Tags

Type your tag names separated by a space and hit enter

Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and Type 2 diabetic subjects.
Diabetes Metab Res Rev 2000 Sep-Oct; 16(5):364-9DM

Abstract

OBJECTIVE

Increased plasma levels of plasminogen activator inhibitor-1 (PAI-1) have been suggested to be a part of the insulin resistance syndrome, and recent data suggest that adipose tissue participates in the production of PAI-1. We examined the expression and insulin regulation of subcutaneous adipose tissue PAI-1 mRNA and its relationship to insulin sensitivity.

DESIGN

A cross-sectional study involving five lean (60.0+/-3.1 years, BMI 23.5+/-0.5 kg/m(2)) and six obese nondiabetic men (56.0+/-3.1 years, BMI 30.4+/-0.7 kg/m(2)), and six obese Type 2 diabetic men (61.4+/-3.2 years, BMI 31.8+/-1.0 kg/m(2)).

MEASUREMENTS

Subcutaneous adipose tissue PAI-1 mRNA and insulin sensitivity were quantified using RT-competitive PCR and euglycemic hyperinsulinemic clamp technique, respectively.

RESULTS

Subcutaneous adipose tissue PAI-1 mRNA levels were higher in obese nondiabetic and Type 2 diabetic men than in lean nondiabetic men. PAI-1 mRNA levels decreased in the three groups during a 240-min euglycemic hyperinsulinemic clamp (P<0.05 for all groups), and a similar reduction was observed during a 240-min saline control study indicating that adipose tissue PAI-1 gene expression has diurnal variation and is not acutely controlled by hyperinsulinemia. The basal PAI-1 mRNA levels correlated positively with BMI, and waist-to-hip ratio; and negatively with whole-body glucose disposal rate in nondiabetic men.

CONCLUSIONS

Subcutaneous adipose tissue PAI-1 mRNA expression is increased in obese nondiabetic or in Type 2 diabetic men. Subcutaneous adipose tissue PAI-1 mRNA expression is increased in proportion to visceral obesity and to the level of whole-body insulin resistance. Subcutaneous adipose tissue PAI-1 mRNA expression is not acutely regulated by insulin, and it is subject to a diurnal variation.

Authors+Show Affiliations

Department of Medicine, Division of Geriatrics, Helsinki University Central Hospital, Helsinki, Finland. heikki_koistinen@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11025560

Citation

Koistinen, H A., et al. "Subcutaneous Adipose Tissue Expression of Plasminogen Activator Inhibitor-1 (PAI-1) in Nondiabetic and Type 2 Diabetic Subjects." Diabetes/metabolism Research and Reviews, vol. 16, no. 5, 2000, pp. 364-9.
Koistinen HA, Dusserre E, Ebeling P, et al. Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and Type 2 diabetic subjects. Diabetes Metab Res Rev. 2000;16(5):364-9.
Koistinen, H. A., Dusserre, E., Ebeling, P., Vallier, P., Koivisto, V. A., & Vidal, H. (2000). Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and Type 2 diabetic subjects. Diabetes/metabolism Research and Reviews, 16(5), pp. 364-9.
Koistinen HA, et al. Subcutaneous Adipose Tissue Expression of Plasminogen Activator Inhibitor-1 (PAI-1) in Nondiabetic and Type 2 Diabetic Subjects. Diabetes Metab Res Rev. 2000;16(5):364-9. PubMed PMID: 11025560.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and Type 2 diabetic subjects. AU - Koistinen,H A, AU - Dusserre,E, AU - Ebeling,P, AU - Vallier,P, AU - Koivisto,V A, AU - Vidal,H, PY - 2000/10/12/pubmed PY - 2001/2/28/medline PY - 2000/10/12/entrez SP - 364 EP - 9 JF - Diabetes/metabolism research and reviews JO - Diabetes Metab. Res. Rev. VL - 16 IS - 5 N2 - OBJECTIVE: Increased plasma levels of plasminogen activator inhibitor-1 (PAI-1) have been suggested to be a part of the insulin resistance syndrome, and recent data suggest that adipose tissue participates in the production of PAI-1. We examined the expression and insulin regulation of subcutaneous adipose tissue PAI-1 mRNA and its relationship to insulin sensitivity. DESIGN: A cross-sectional study involving five lean (60.0+/-3.1 years, BMI 23.5+/-0.5 kg/m(2)) and six obese nondiabetic men (56.0+/-3.1 years, BMI 30.4+/-0.7 kg/m(2)), and six obese Type 2 diabetic men (61.4+/-3.2 years, BMI 31.8+/-1.0 kg/m(2)). MEASUREMENTS: Subcutaneous adipose tissue PAI-1 mRNA and insulin sensitivity were quantified using RT-competitive PCR and euglycemic hyperinsulinemic clamp technique, respectively. RESULTS: Subcutaneous adipose tissue PAI-1 mRNA levels were higher in obese nondiabetic and Type 2 diabetic men than in lean nondiabetic men. PAI-1 mRNA levels decreased in the three groups during a 240-min euglycemic hyperinsulinemic clamp (P<0.05 for all groups), and a similar reduction was observed during a 240-min saline control study indicating that adipose tissue PAI-1 gene expression has diurnal variation and is not acutely controlled by hyperinsulinemia. The basal PAI-1 mRNA levels correlated positively with BMI, and waist-to-hip ratio; and negatively with whole-body glucose disposal rate in nondiabetic men. CONCLUSIONS: Subcutaneous adipose tissue PAI-1 mRNA expression is increased in obese nondiabetic or in Type 2 diabetic men. Subcutaneous adipose tissue PAI-1 mRNA expression is increased in proportion to visceral obesity and to the level of whole-body insulin resistance. Subcutaneous adipose tissue PAI-1 mRNA expression is not acutely regulated by insulin, and it is subject to a diurnal variation. SN - 1520-7552 UR - https://www.unboundmedicine.com/medline/citation/11025560/Subcutaneous_adipose_tissue_expression_of_plasminogen_activator_inhibitor_1__PAI_1__in_nondiabetic_and_Type_2_diabetic_subjects_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=1520-7552&amp;date=2000&amp;volume=16&amp;issue=5&amp;spage=364 DB - PRIME DP - Unbound Medicine ER -